A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib

Clin Lung Cancer. 2021 Nov;22(6):e799-e803. doi: 10.1016/j.cllc.2021.03.012. Epub 2021 Mar 26.
No abstract available

Keywords: Crizotinib; EML4-ALK; Gene testing; Partial response; SCLC.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Crizotinib / administration & dosage
  • Crizotinib / pharmacology*
  • Humans
  • Male
  • Oncogene Proteins, Fusion / drug effects*
  • Oncogene Proteins, Fusion / genetics*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / pharmacology*
  • Treatment Outcome

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Crizotinib